Insulet (PODD) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Powered by 
Analysis
Insulet (PODD) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.76 Bn | 175.16 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.77 Bn | 122.55 Bn | 1.96 Bn |
| 3 | Medtronic | 117.20 Bn | 108.39 Bn | 6.34 Bn |
| 4 | Stryker | 104.01 Bn | 100.53 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.80 Bn | 45.55 Bn | 1.35 Bn |
| 7 | Alcon | 33.03 Bn | 31.58 Bn | 1.68 Bn |
| 8 | Dexcom | 32.18 Bn | 30.23 Bn | 830.00 Mn |
| 9 | Steris | 20.71 Bn | 20.23 Bn | 684.20 Mn |
| 10 | Insulet | 9.35 Bn | 8.82 Bn | 562.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.13% |
| Dec 31, 2025 | 51.37% |
| Sep 30, 2025 | 49.83% |
| Jun 30, 2025 | 9.34% |
| Mar 31, 2025 | 80.02% |
| Dec 31, 2024 | 82.31% |
| Sep 30, 2024 | 149.60% |
| Jun 30, 2024 | 166.61% |
| Mar 31, 2024 | 63.56% |
| Dec 31, 2023 | 59.87% |
| Sep 30, 2023 | 99.10% |
| Jun 30, 2023 | 78.55% |
| Mar 31, 2023 | 41.25% |
| Dec 31, 2022 | 35.03% |
| Sep 30, 2022 | -18.48% |
| Jun 30, 2022 | -35.13% |
| Mar 31, 2022 | 36.77% |
| Dec 31, 2021 | 39.08% |
| Sep 30, 2021 | 43.31% |
| Jun 30, 2021 | -42.65% |